Resilience Isn't One-Size-Fits-All
In this new chapter, the podcast will dive deeper into the many dimensions of human resilience, focusing on them one theme at a time. Today, Ben explains why the podcast is evolving and why hearing multiple perspectives on a single topic is crucial — because resilience is never one-size-fits-all. He also reveals the first theme in the upcoming series, which kicks off Monday, July 7th.
To listen to the episodes mentioned in today's episode, visit the links below:
Rich Fierro: https://radio.foxnews.com/2023/12/10/a-question-of-fight-or-flight/
Maya Regev: https://radio.foxnews.com/2024/04/22/surviving-hamas-one-womans-story-of-survival/
Amanda Boxtel: https://radio.foxnews.com/2024/01/22/the-other-side-of-lifes-detours/
Dr. Lucy Hone: https://radio.foxnews.com/2024/07/01/rewiring-your-brain-to-be-resilient-with-dr-lucy-hone/
Dr. Joe Alderete: https://radio.foxnews.com/2024/07/08/the-principles-of-rehabilitation/
Follow Benjamin on X: @BenjaminHallFNC
Learn more about your ad choices. Visit podcastchoices.com/adchoices
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
CBD Pouches Market to Hit Valuation of US$ 535.62 Million By 2033
CBD pouches market is currently defined by a surge in consumer demand for convenient, smoke-free wellness products. Innovation in flavors and precise, moderate dosages are attracting a broader, health-conscious demographic, solidifying its mainstream appeal. Chicago, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The global CBD pouches market was valued at US$ 90.12 million in 2024 and is expected to reach US$ 535.62 million by 2033, growing at a CAGR of 21.9% during the forecast period 2025–2033. The market is maturing rapidly, driven by specific consumer preferences and strategic product positioning. The dominance of the 10-20 mg dosage illustrates a consumer base that is increasingly educated, seeking tangible wellness benefits without overwhelming effects. This segment has become the core of the CBD pouches market by successfully bridging the gap between cautious new users and experienced consumers. The preference for flavored options underscores the importance of the user experience; by removing the barrier of unpleasant taste, brands have made CBD consumption more accessible and enjoyable, integrating it into daily routines as a lifestyle product rather than a purely medicinal one. This is a key growth engine for the entire market. Download Sample Pages: The resilience of offline retail channels in the CBD pouches market speaks volumes about the consumer's need for trust and immediacy in this sector. In an industry still navigating complex regulations, the ability to interact with a product and a knowledgeable salesperson provides a level of assurance that online platforms struggle to match. Physical stores serve as crucial educational hubs, building consumer confidence and fostering loyalty through direct engagement. Looking ahead, the synergy between these dominant segments—a trusted, palatable product at an effective dose, available in a reliable retail environment—will continue to define the growth trajectory of the industry. Key Findings in CBD Pouches Market Market Forecast (2033) US$ 535.62 million CAGR 21.9% Largest Region (2024) North America (59%) By Content 10-20mg (52%) By Type Flavored (88%) By Distribution Offline (68%) Top Drivers Increasing consumer awareness of CBD's potential health and wellness benefits. Growing demand for smokeless and discreet alternatives to conventional tobacco. Progressive legalization of cannabis products, increasing accessibility and social acceptance. Top Trends Rising interest in microdosing and low-dose CBD product formulations. Enhanced focus on product transparency through third-party lab testing results. Innovation in formulations to include functional ingredients beyond just CBD. Top Challenges Navigating the complex and often inconsistent legal and regulatory landscape. Strict advertising and marketing restrictions imposed by major online platforms. High market competition and content saturation for key search terms. U.S. Hemp Production Forms a Robust Market Foundation The viability of the CBD pouches market is fundamentally tied to its agricultural backbone. In 2024, the United States saw 45,294 acres of industrial hemp planted in the open. Of this, a total of 32,694 acres were harvested. Data from 8,153 surveyed hemp producers reveals a highly specialized cultivation landscape. Floral hemp, the primary source for CBD, accounted for 20.8 million pounds produced from 11,827 harvested acres. This reflects a significant yield increase of 669 pounds per acre compared to the previous year, with an average yield of 1,757 pounds per acre. In parallel, production under protection (e.g., greenhouses) utilized 3.52 million square feet, yielding 356,000 clones and transplants, 49,420 pounds of floral hemp, and 2,364 pounds of seed hemp. Other segments included fiber hemp, with 60.4 million pounds produced from 18,855 acres at an average yield of 3,205 pounds per acre. Grain hemp production stood at 3.41 million pounds from 4,863 acres, while seed hemp production in the open yielded 697,000 pounds from 2,160 acres. Unpacking the Economic Realities of Raw Material Pricing The total value of U.S. hemp production in 2024 reached an impressive $445 million. This was comprised of $417 million from hemp grown in the open and $28.7 million from crops under protection. Floral hemp was the most valuable segment at $386 million, followed by seed hemp at $16.9 million, fiber hemp at $11.2 million, and grain hemp at $2.62 million. These values translate into specific wholesale costs that shape the final price within the CBD pouches market. In 2024, CBD biomass costs ranged from a low of $8.50 to a high of $230 per pound. Farmers often received $150 per pound for machine-trimmed outdoor CBD flower, while premium indoor-grown flower commanded an average of $600 per pound. For biomass with a 10% CBD content, the rate was $3.00 per pound. Looking ahead, Q2 2025 price projections per metric ton of hemp are $3,998 in the USA, $1,330 in China, $3,417 in Germany, and $3,210 in the Middle East, highlighting global cost differentials. Product Innovation and Composition Define Competitive Edges Product differentiation is a critical success factor in the competitive CBD pouches market. Market leader Cannadips exemplifies this trend with a standard tin containing 15 pouches, each with 10mg of water-dispersible CBD for a total of 150mg. Their 5x strength line significantly increases potency to 50mg of CBD per pouch, totaling 750mg per tin. Across these lines, the company offers a combined 8 flavors, including American Spice and Tropical Mango. Competitor Chill CBD Pouches offers products with a potency of 10-15mg per pouch. This innovation is happening within regulatory guardrails; for instance, French regulations in 2024 mandated a daily consumption limit of 50mg of CBD per person, a key constraint for product formulation in that region. The diversity of strength and flavor profiles underscores the industry's response to varied consumer demands. Corporate Strategy and Market Expansion Drive Brand Growth Strategic expansion is a dominant theme in the CBD pouches market as companies seek to establish a broader footprint. In a landmark move outside its home state, Cannadips announced in November 2024 its entry into the Arkansas market. This move expands its reach beyond the 6,000 stores where its hemp pouches are already available. Other cannabis-related companies are also expanding, with Aurora Cannabis acquiring MedReleaf Australia in February 2024 and Curaleaf acquiring Northern Green Canada in May 2024 to bolster international operations. New entrants are also making waves; Juana Dips, launched in 2024, already sold its cannabis pouches in 2 states (Colorado and Massachusetts) as of early 2025 and was in licensing talks with 13 companies in other states to rapidly scale its brand presence. Navigating the Complex and Shifting Global Regulatory Maze The regulatory environment remains a pivotal and fluid element influencing the CBD pouches market. In the U.S., the FDA Commissioner testified before a House committee on April 11, 2024, reaffirming the agency's position on needing a new regulatory pathway for CBD products. Progress is being made, as in June 2025, the FDA received 2 public comments supporting the addition of a "cannabinoid hemp product" category to its safety reporting system. In Europe, Switzerland introduced a new tobacco law in October 2024 that also governs industrial hemp flowers. Meanwhile, a February 2024 bill signed into law legalized medical cannabis in Ukraine, opening a new market. Conversely, Italy imposed significant restrictions on "cannabis light" in 2024 and, via a decree on June 27, 2024, classified CBD as a narcotic medicinal substance, creating substantial market hurdles. Clinical Research and Scientific Inquiry Bolster Consumer Trust Credibility and consumer trust are being built through rigorous scientific validation. A significant multicenter trial in India with 178 participants, with results reported in 2024, assessed an oral CBD solution for anxiety. Further research from a 2021 clinical trial involving 8 weeks of daily CBD use showed potential for enhancing natural killer cells. In 2025, a UCSD clinical trial studying CBD for early psychosis remains active, with plans to randomize approximately 120 patients. Demonstrating the ongoing effort to understand the substance, a study with 6 healthy adults characterized the urinary pharmacokinetic profile of 100-mg oral and vaporized CBD, with its proceedings published in October 2024. This growing body of clinical evidence is crucial for the long-term mainstream acceptance of the CBD pouches market. A Surge in Innovation and Intellectual Property Filings The future of the CBD pouches market is being written in its patent filings. A systematic review published in May 2025, which initially retrieved 99 patents filed between 2012 and 2024, ultimately included 15 relevant patents on cannabis drug delivery systems, highlighting the pace of innovation. Specific to the pouch format, a patent application for a "Cannabinoid pouch" was published on July 18, 2024. Another key filing, patent application WO2025116961A1 for cannabis compositions and oral products, is cited for 2025, indicating future product pipelines. These filings demonstrate a clear industry trend toward protecting novel formulations and delivery technologies, which will serve as a key competitive differentiator and barrier to entry in the coming years. Expanding Retail Footprints and Strategic Distribution Channels Accessibility is key to market growth, and distribution channels are widening significantly. In a pivotal move in 2024, pharmacies in France were authorized to sell CBD-based food supplements, opening a trusted and mainstream retail avenue. Trade shows remain a vital platform for brand visibility. Cannadips showcased its products at the 2024 InterTabac Trade Fair in Dortmund, Germany, from September 19-21. The company occupied booth number A29 in hall number 6, demonstrating a strategic investment in reaching European distributors and retailers. This expansion into both pharmaceutical and international trade channels is essential for moving CBD pouches from specialty items to everyday consumer goods, directly fueling growth in the CBD pouches market. Need a Customized Version? Request It Now: A Dynamic Competitive Landscape and International Opportunities The competitive field is intensifying with a mix of established and new players. An August 2025 report identified 11 key players in the U.S. market, including Cannadips, VELO CBD, and FlowBlend. A separate August 2024 report profiled 10 major players, among them METOLIUS HEMP COMPANY and Canndid. The launch of new companies like Juana Dips in 2024 indicates a healthy and growing ecosystem. This competition is unfolding on a global stage with distinct international rules. For instance, following 2024 legal changes, adults in Malta can possess 7 grams of cannabis and cultivate 4 plants, though public consumption carries a 500 Euro fine. As of April 2024, Switzerland has an updated enforcement aid for CBD, and product approvals for the entire bloc of 27 EU member states are under review, creating a complex but opportunity-rich international CBD pouches market. Global CBD Pouches Market Major Players: Comp9 Canndid Chillbar FlowBlend Cannadips Vibe CBD+CBG Jake's Mint Chew Nicopods ehf. V&YOU Metolius Hemp Company Key Market Segmentation: By Type Flavored Unflavored By Content Up to 10 mg 10 mg-20 mg Others By Distribution Channel Online Offline By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
Gizmodo
21 minutes ago
- Gizmodo
FDA Rehires Controversial Biologics Chief Just Days After Trump Fired Him
The circus was performing at the Food and Drug Administration this weekend, apparently. The FDA has hired Vinay Prasad to oversee the Center for Biologics Evaluation and Research—less than two weeks after he left that same role. Endpoints News was the first to report on Prasad's rehiring on Saturday. He was initially reportedly fired by President Donald Trump himself, following growing pressure from Laura Loomer and other conservative voices who criticized him over the agency's regulation of a gene therapy developed by Sarepta Therapeutics. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' Andrew Nixon, communications officer for the Department of Health and Human Services, told Gizmodo. Prasad is a hematologist-oncologist and epidemiologist formerly based at the University of California-San Francisco. He has also regularly written editorials, articles, and studies critical of the medical establishment and public health agencies like the FDA. While some of his critiques have enjoyed support from many in the public health field, such as calling for a stricter standard when approving new therapies, others have been more controversial. The often-combative Prasad has criticized the government's initial response to covid-19 as too restrictive, argued that many people didn't need the covid-19 vaccine, including children, and downplayed the health impacts of long covid, to name a few examples. FDA Commissioner Marty Makary first hired Prasad to head CBER in early May. He was also additionally named the FDA's chief medical and scientific officer. But it didn't take long for Prasad to collect more enemies. Under his reign, the FDA butted heads with Sarepta Therapeutics over its Elevidys gene therapy treatment for the rare and life-shortening condition Duchenne muscular dystrophy (DMD). Following the deaths of three patients linked to the drug, the FDA ordered Sarepta in mid-July to pause all shipments of the therapy until further notice. But 10 days later, the agency reversed course and recommended the drug to patients capable of walking. Days after that, Prasad left the FDA. Though the FDA stated officially that Prasad left of his own volition to 'spend more time with his family,' Politico soon reported that Trump had pushed for Prasad's firing over the objections of Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Makary. Prior to Trump's intervention, several right-wing influencers—most notably Laura Loomer—called for Prasad's head over his management of the Sarepta situation. Loomer and others also maligned Prasad as a 'progressive marxist' and saboteur to Trump and the 'Make America Healthy Again' agenda, pointing out that he had once insulted Trump. Prasad's return isn't entirely surprising, though. Days after he left, FDA Commissioner Makary stated that he was working to bring back Prasad. At the time, Makary also called the reports of Trump firing him false, and HHS seems to now be sticking to a similar script. 'Neither the White House nor HHS will allow the fake news media to distract from the critical work the FDA is carrying out under the Trump administration,' Nixon said. Whatever the exact chain of events, Prasad's comeback may signal that Loomer's influence over the White House isn't quite as ironclad as it's appeared. Or maybe it's just another sign that no one there really has any clue what is happening at any given time.
Washington Post
23 minutes ago
- Washington Post
Ousted FDA vaccine chief Vinay Prasad is returning to the agency
WASHINGTON — A Food and Drug Administration official is getting his job back as the agency's top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday. Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump. A longtime a critic of FDA's standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne's muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines. Prasad's decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen. Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy's use. Loomer posted online that Prasad was 'a progressive leftist saboteur,' noting his history of praising liberal independent Sen. Bernie Sanders. But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
